

ImmunoPrecise Antibodies Ltd

09:25 17 Apr 2020

ImmunoPrecise Antibodies says coronavirus research activities for experimental vaccines and therapeutics advancing

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCQB:IPATF) on Friday provided an update on its research activities for the coronavirus (COVID-19), outlining its workflow for experimental vaccines and therapeutics for the research community.

In a statement, the company said its multi-targeting approach combines various SARS-CoV-2 spike protein forms with its diverse technologies. The SARS-CoV-2 virus causes COVID19, which is the disease.

ImmunoPrecise said it anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, immunizing Ligand Pharmaceuticals' (NASDAQ:LGND) OmniRat animals using the company's Rapid Prime protocol followed by its B cell Select and hybridoma generation in parallel with human, naive phage library screening.

READ: ImmunoPrecise Antibodies unveils new therapy approach in bid to tackle coronavirus

Subsequent high-throughput binding assays, computational Artemis optimization, and protein interaction analyses permit faster preclinical lead selection, ImmunoPrecise said.

"In addition to using our antibody discovery platforms for the potentially rapid identification of a diverse panel of fully SARS-CoV-2-specific antibodies, we aim to target additional novel epitopes which are likely inaccessible to conventional antibody formats by screening our in-house, highly complex, VHH repertoire (collection of variable regions of heavy chain antibodies, a region which binds to the target immunogen)," said Ilse Roodink, chairwoman of Talem Therapeutics' scientific advisory committee and Coronavirus global project leader. Talem is an ImmunoPrecise subsidiary.

"Due to the relative high sequence homology of VHHs with human antibodies, extensive humanization is not required and therefore, our discovery strategy mixture will significantly contribute to the fast generation of a monoclonal antibody cocktail with broad epitope coverage and diverse functionalities, which is key to successful development of an effective, long-lasting therapy with a high safety profile," Roodink added.

Apart from the various SARS-CoV-2 spike protein forms which have been produced for use in therapeutic development, data obtained during the discovery of lead antibody candidates may be of significant value in the reverse-engineering of vaccine candidates used to formulate an effective low-risk, vaccine, ImmunoPrecise said.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 2.44

Market Cap: \$195.14 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: IPA

Listing: TSX-V

52 week	High	Low
	3.14	0.5

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).